Lawsuit challenges Cipla's buyout of InvaGen

India's Cipla announced a $550 million deal last month to buy New York-based InvaGen and a related company in its first foray into manufacturing in the U.S. But a hitch in the deal has developed as New Jersey-based PuraCap Pharmaceutical has filed suit claiming InvaGen breached unspecified obligations to it but "improperly negotiating" with Cipla, the Economic Times reports. Story | More

Suggested Articles

Gilead expects to sell 1 million to 1.5 million treatment courses of remdesivir in 2020. That means about $3.5 billion in sales, one analsyt figures.

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Warp Speed's largest outlay to date, the funding will cover development and manufacturing scale-up of a vaccine that uses proven Sanofi technology.